The long-simmering tensions surrounding the 340B Drug Pricing Program have reached a boiling point. Eli Lilly, one of the world’s largest pharmaceutical manufacturers, has officially begun cutting off 340B pricing for hospitals that refuse to submit granular claims data for its products. This move marks a significant escalation in the pharmaceutical industry’s aggressive push for greater oversight of a program that has become both a lifeline for safety-net providers and a primary target for critics who argue it has spiraled into a source of systemic abuse.
For the affected hospitals, the consequences are immediate and severe. By being stripped of their 340B status for Lilly products, these institutions must now purchase life-saving medications at wholesale prices—losing the 20% to 50% discounts that are the hallmark of the program. As the American Hospital Association (AHA) and 340B Health warn, this could fundamentally destabilize the financial footing of providers serving the most vulnerable populations.
Chronology of a Regulatory Collision
The current impasse is the result of months of hardening positions between manufacturers and providers.
- January 2024: Eli Lilly publicly announced that it would begin requiring all participating hospitals to submit detailed claims data for all of its drugs dispensed through the 340B program. Lilly argued that this data was essential to prevent "drug diversion" and "duplicate discounts," where a drug might be improperly discounted twice.
- Early 2024: While the policy was announced, immediate enforcement was not initially triggered. Lilly engaged in a period of attempted voluntary compliance, urging hospitals to hand over data voluntarily.
- Mid-2024: A coalition of well-resourced hospitals, citing legal concerns and the potential for the exposure of proprietary data, refused to comply.
- Late 2024/Early 2025: Frustrated by what it described as a "lack of cooperation," Lilly issued a formal ultimatum. In a letter to the Health Resources and Services Administration (HRSA), the company characterized the data requirement as a "crucial step" to root out fraud, noting that the decision to cut off discounts was taken "reluctantly."
- The Current Moment: As of this month, Lilly has followed through on its threat, terminating 340B pricing for non-compliant facilities. This move has prompted an outcry from hospital associations, which argue that Lilly is attempting to rewrite federal law through unilateral corporate policy.
Supporting Data: The Exponential Growth of 340B
The intensity of this dispute is underscored by the sheer scale of the 340B program’s growth. Originally established in the early 1990s as a targeted mechanism to help cash-strapped safety-net providers afford expensive prescription drugs, the program has ballooned into a multi-billion-dollar enterprise.
According to the most recent HRSA data, hospitals purchased a record $66.3 billion in discounted drugs under the 340B program in 2023. To put this into perspective, this represents a growth of more than 50% from the $43.9 billion recorded just two years prior in 2021.
Analysts, including those at the Congressional Budget Office (CBO), point to several structural drivers for this expansion:
- System Integration: Hospitals have increasingly acquired independent clinics and expanded their pharmacy networks, bringing more volume under the 340B umbrella.
- Specialty Drug Inflation: The increasing reliance on high-cost biologic drugs and specialty medications has naturally inflated the dollar volume of discounts.
- Lack of Transparency: Critics point out that the current 340B statute provides no requirements for how providers utilize their savings, nor does it mandate transparent reporting on how these funds support patient care.
Official Responses and Legal Arguments
The battle lines are drawn between two fundamentally different interpretations of the 340B statute.
The Pharmaceutical Perspective
Eli Lilly maintains that its data submission policy is consistent with decades of federal guidance. The company argues that because the 340B statute prohibits manufacturers from being held liable for "duplicate discounts" (where a drug is discounted under both 340B and the Medicaid rebate program), they have an inherent right to verify the legitimacy of each 340B claim. From Lilly’s viewpoint, the lack of transparency in the current system makes it impossible to prevent systemic fraud, and they believe they are acting as responsible stewards of their own supply chain.
The Hospital Perspective
Hospital groups, led by the AHA and 340B Health, view Lilly’s actions as an illegal overreach. Maureen Testoni, president and CEO of 340B Health, stated clearly, "We believe Lilly’s actions violate the law and are an unprecedented attempt to rewrite the 340B rules without congressional approval."
Hospitals argue that the 340B statute is a federal mandate that does not provide manufacturers the authority to attach "strings" to the discounts. By conditioning these savings on the disclosure of internal claims data, hospitals argue that Lilly is essentially bypassing the legislative process to exert control over hospital operations. Rick Pollack, president and CEO of the AHA, has called on HRSA and the Department of Health and Human Services (HHS) to intervene, asserting that the government cannot stand by while drugmakers "skirt their obligations" for their own financial benefit.
Broader Implications: A Precedent for Reform?
The implications of this standoff extend far beyond Eli Lilly. The healthcare industry is watching closely, fearing a "domino effect" where other manufacturers follow suit. Indeed, Novo Nordisk is already implementing its own data-sharing requirements, signaling that the pharmaceutical industry is coalescing around a strategy of forced transparency.
The Future of 340B Payment Structures
This is not the first time drugmakers have attempted to reshape the program. In 2024, a group of pharmaceutical companies attempted to shift the 340B model from upfront discounts to a "rebate" model, where hospitals would pay full price for drugs and receive the savings later, pending verification. That effort failed when federal judges and HRSA regulators agreed that such a fundamental change required explicit authorization from Congress.
The question remains: will the data-sharing mandate meet the same fate?
The Role of HRSA and the Executive Branch
HRSA remains in a precarious position. While the agency has historically been a defender of the 340B program’s original structure, the political environment is shifting. Recent attempts by the Trump administration to pilot a rebate program—though eventually scrapped following hospital lawsuits—demonstrate that there is significant appetite within the executive branch to re-evaluate the 340B status quo.
The industry is now waiting for a definitive signal from federal regulators. If HRSA remains silent or tacitly approves of Lilly’s actions, it could signal a permanent shift in power, effectively granting manufacturers the leverage to dictate terms to hospitals.
Conclusion: The Urgency of Congressional Intervention
The conflict between Eli Lilly and the hospital industry highlights a fundamental flaw in the current 340B landscape: the statute is aging, opaque, and increasingly out of sync with the modern pharmaceutical market.
As hospitals struggle to absorb the loss of discounts and drugmakers move to enforce private oversight, the primary losers are the patients caught in the middle. Without clear, updated legislative guidance from Congress, the 340B program risks becoming a permanent battleground of litigation and supply chain disruptions.
The era of "voluntary compliance" appears to be over. Whether this leads to a more transparent and sustainable system or to a dismantling of the safety-net discount model remains the most pressing question in healthcare policy today. For now, the standoff continues, and with each passing day, the financial pressure on the nation’s hospitals intensifies, leaving a precarious future for the program that has long been the backbone of care for America’s most vulnerable patients.
